A descriptive case series of hepatotoxicity associated with CFTR modulators and possible relevance of pharmacogenetic polymorphisms in cystic fibrosis patients
Open Access
- 25 June 2026
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 92 (9) , e70660-3264
Abstract
Cystic fibrosis transmembrane conductance regulator (CFTR) modulators are widely used in patients with cystic fibrosis and significantly improve respiratory function and quality of life. However, their effectiveness may be limited by liver damage, which sometimes leads to treatment discontinuation, and the mechanisms underlying this remain poorly understood. This case series explores the role of genetic polymorphisms affecting the enzymes and transporters involved in their pharmacokinetics, as well as detoxification mechanisms (CYP3A4/CYP3A5/ABCB1/SLCO1B1/GSTP1/GSTM1/GSTT1). Six cases of hepatotoxicity under CFTR modulators were assessed using the RECAM score. Among the genetic polymorphisms assessed, CYP3A4*22 (rs35599367) allele had higher allele frequency than in the European population, which usually does not express CYP3A5. This genetic variant, reducing CYP3A activity, could decrease the elimination of CFTR modulators and increase the risk of liver toxicity. Other genetic factors may also be involved. Further studies are needed to confirm these results.Keywords
This publication has 24 references indexed in Scilit:
- Phenotypic and functional characterisation of liver-infiltrating T-cells in a case of CFTR modulator induced drug-induced liver injuryJournal of Cystic Fibrosis, 2025
- Quantitative Systems Toxicology Predicts Ivacaftor‐Induced Oxidative Stress Contributes to CFTR Modulator HepatotoxicityClinical Pharmacology & Therapeutics, 2025
- Immunogenic adverse events to CFTR modulators – An international surveyJournal of Cystic Fibrosis, 2025
- Adverse events to elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis due to elevated drug exposure?: A case seriesJournal of Cystic Fibrosis, 2025
- Introduction of Ivacaftor/Lumacaftor in Children With Cystic Fibrosis Homozygous for F508del in the Netherlands: A Nationwide Real‐Life StudyPediatric Pulmonology, 2025
- Physiologically‐based pharmacokinetic modeling of the drug–drug interaction between ivacaftor and lefamulin in cystic fibrosis patientsCPT: Pharmacometrics & Systems Pharmacology, 2024
- A revised electronic version of RUCAM for the diagnosis of DILIHepatology, 2022
- Drug-induced liver injury from elexacaftor/ivacaftor/tezacaftorJournal of Cystic Fibrosis, 2022
- Hypersensitivity to antibiotics in patients with cystic fibrosisJournal of Cystic Fibrosis, 2014
- Glutathione S‐transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug‐induced liver injury†Hepatology, 2008